ArticleJournal of pharmaceutical health care and sciences2025
Baseline serum albumin level as a predictive factor for the efficacy of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer: a retrospective cohort study.
Article in Journal of pharmaceutical health care and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrifluridine/tipiracil (FTD/TPI) combined with bevacizumab (BEV) has become a standard later-line therapy for metastatic colorectal cancer (mCRC). However, predictive biomarkers of treatment efficacy remain limited. Serum albumin (Alb)—reflecting nutritional and inflammatory status—has been reported as a prognostic factor in various malignancies, but its predictive value in patients receiving FTD/TPI plus BEV is unclear. We examined whether baseline Alb levels are linked to treatment outcomes in patients with metastatic CRC receiving FTD/TPI plus BEV, aiming to clarify if Alb could serve as a predictive marker of therapeutic efficacy.
methodsWe retrospectively analyzed patients with unresectable or recurrent mCRC treated with FTD/TPI plus BEV at Fukuyama Medical Center between December 2017 and March 2024. Patients were divided into High- or Low-Alb groups based on an optimal cutoff derived from receiver operating characteristic (ROC) analysis for progression-free survival (PFS). The primary endpoint was PFS, and the secondary endpoint was overall survival (OS). Survival outcomes were assessed using the Kaplan–Meier method and Cox proportional hazards models.
resultsSixty-nine patients were included (median age, 69 years). ROC analysis identified an Alb cutoff of 3.7 g/dL (area under the curve: 0.740). Using this cutoff, 39 patients (56.5%) were included in the High-Alb group. Patients in the High-Alb group had significantly lower lactate dehydrogenase (LDH) and C-reactive protein levels than those in the Low-Alb group. The median PFS (5.2 vs. 3.0 months; p < 0.01) and OS (15.6 vs. 6.0 months; p < 0.01) were significantly longer in the High-Alb group than in the Low-Alb group. In the multivariate analysis, Alb ≥3.7 g/dL was independently associated with improved PFS (hazard ratio [HR]: 0.40, 95% confidence interval [CI]: 0.22–0.73, p = 0.003), whereas LDH ≥338 U/L was associated with shorter PFS (HR: 2.31, 95% CI: 1.28–4.32, p = 0.009).
conclusionsBaseline serum Alb levels were associated with survival outcomes in patients with mCRC treated with FTD/TPI plus BEV. Thus, Alb may represent a simple and clinically accessible marker with potential predictive value. Initiating FTD/TPI plus BEV before a substantial decline in nutritional or inflammatory status may help achieve more favorable outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.